Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 14/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 14/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280176 | 0.87 | CTSD (0.40) | GRIN1GRIN2BGRM1 | |
| SCHEMBL6285997 | 0.80 | GRM1 (0.40) | GRIN1GRIN2BGRM1MIF | |
| SCHEMBL6284962 | 0.78 | MIF (0.35) | GRIN1GRIN2BGRM1MIF | |
| SCHEMBL6283846 | 0.77 | GABRA1 (0.52) | — | |
| SCHEMBL6283855 | 0.77 | GABRA1 (0.44) | — | |
| SCHEMBL30019316 | 0.68 | PARP10 (0.41) | GRIN1GRIN2BCYP17A1ALDH1A1CYP3A4 | |
| SCHEMBL6284455 | 0.66 | GABRA1 (0.56) | GRM1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL25665451 | 0.64 | ALDH1A1 (0.41) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL30583061 | 0.60 | PARP10 (0.44) | GRIN1GRIN2BCYP17A1CYP1A2CYP3A4 | |
| SCHEMBL2652002 | 0.60 | MAP4K4 (0.44) | CYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887885-B2 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | MERCK SHARP & DOHME LTD | 2005-05-03 | — | — | US | claimed |
| US-6887885-B2 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | MERCK SHARP & DOHME LTD | 2005-05-03 | — | — | US | disclosed |
| US-20040132767-A1 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132767-A1 | Imidazo[4,5-c]pyridin-4-one analogues as GABAA receptor ligands | GABRA1, GABRA2, GABRA3 | GRIN1 74/4885GRIN2B 39/4885GRM1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.